financetom
Business
financetom
/
Business
/
Profound Medical Expands Access to TULSA-PRO in Australia, New Zealand Through Getz Healthcare Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Profound Medical Expands Access to TULSA-PRO in Australia, New Zealand Through Getz Healthcare Deal
Nov 12, 2025 8:54 AM

11:34 AM EST, 11/12/2025 (MT Newswires) -- Profound Medical ( PROF ) announced Wednesday an exclusive agreement with Getz Healthcare to distribute its TULSA-PRO system in Australia and New Zealand, extending the global reach of its AI-driven, MRI-guided prostrate therapy technology.

The TULSA Procedure, powered by Profound's TULSA-PRO system, uses robotically controlled, MRI-guided ultrasound to precisely ablate prostate tissue without incisions, enabling personalized treatment while safeguarding nearby structures.

Profound said it plans to expand its direct sales network in North America while partnering with global distributors to drive international adoption of its TULSA-PRO technology.

Shares of Profound Medical ( PROF ) were down 2.8% in recent trading.

Price: 6.20, Change: -0.18, Percent Change: -2.75

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Turning Vision Into Value: Cie Portfolio Win as Nativo Is Acquired for $120M
Turning Vision Into Value: Cie Portfolio Win as Nativo Is Acquired for $120M
Nov 13, 2025
IRVINE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cie, a venture studio, announced today that its portfolio company Nativo, a leading advertising technology provider, has entered into a definitive agreement to be acquired by Life360 ( LIF ) . The transaction, valued at approximately $120 million in cash and stock, marks another successful outcome of Cie’s venture studio model. Nativo joins...
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Nov 13, 2025
Gilead Sciences Inc ( GILD ). on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). • GILD shares are testing new highs. Check the market position here....
Intuitive Surgical Insider Sold Shares Worth $435,000, According to a Recent SEC Filing
Intuitive Surgical Insider Sold Shares Worth $435,000, According to a Recent SEC Filing
Nov 13, 2025
01:58 PM EST, 11/13/2025 (MT Newswires) -- Craig H Barratt, Director, on November 12, 2025, sold 750 shares in Intuitive Surgical ( ISRG ) for $435,000. Following the Form 4 filing with the SEC, Barratt has control over a total of 27,198 common shares of the company, with 27,198 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1035267/000127762025000008/xslF345X05/edgardoc.xml Price: 568.86, Change: -3.60, Percent Change:...
Serve Robotics Shares Skid: What's Going On?
Serve Robotics Shares Skid: What's Going On?
Nov 13, 2025
Serve Robotics Inc ( SERV ) shares are trading lower on Thursday. The company disclosed its financial results for the third quarter. SERV is underperforming relative to peers. Get the market research here. What To Know: Serve Robotics ( SERV ) reported quarterly losses of 40 cents per share, versus the analyst consensus estimate for losses of 33 cents per share....
Copyright 2023-2026 - www.financetom.com All Rights Reserved